Skip to main content

Table 2 Number of subjects experiencing first MACE and mean observation time in the semaglutide trials

From: Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

 

Semaglutide

Comparator

n

N

(%)

Observation time, total (mean), patient-years

n

N

(%)

Observation time, total (mean), patient-years

CVOTs

167

3,239

5.2

5,464 (1.69)

217

3,241

6.7

5,434 (1.68)

Glycemic efficacy trials

55

7,269

0.8

7,636 (1.05)

34

3,896

0.9

4,000 (1.03)

Overall

222

10,508

2.1

13,099 (1.25)

251

7,137

3.5

9,434 (1.32)

  1. Observation time is curtailed at a maximum of 109 weeks to align with the analysis timeframe
  2. % proportion of subjects, CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events, n number of subjects with events, N number of subjects in full analysis set